NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Scopus
BioPharma Inc. (Nasdaq: SCPS) today announced the closing of
its initial public offering. The underwriters for the initial
public offering exercised their over-allotment option in full.
The company offered 575,000 shares of common stock, including
shares issued for the over-allotment option, at a public offering
price of $5.50 per share.
The company's common stock trades on the Nasdaq Global Market
under the ticker symbol "SCPS".
The Benchmark Company, LLC acted as Sole Bookrunning Manager and
Joseph Gunnar & Co., LLC acted
as Co-Manager for the offering.
Greenberg Traurig, LLP acted as counsel to the company.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as
counsel to the underwriters.
Scopus BioPharma intends to use the proceeds of the offering
principally to further development of the company's lead drug
candidate, a novel, targeted immuno-oncology gene therapy for the
treatment of multiple cancers.
An offering statement relating to the shares of common stock was
filed with the U.S. Securities and Exchange Commission ("SEC") and
became qualified on December 14,
2020. An offering circular relating to the offering was
filed with the SEC and is available on the SEC's website at
http://www.sec.gov. Copies of the offering circular may be obtained
by contacting: The Benchmark Company, LLC, Attention: Prospectus
Department, 150 E. 58th Street, 17th Floor, New York, NY 10155, by calling (212) 312-6700
or by e-mail at prospectus@benchmarkcompany.com; or Joseph Gunnar & Co., LLC, Attention:
Prospectus Department, 30 Broad Street, 11th Floor, New York, NY 10004, by calling (212) 440-9600
or by email at prospectus@jgunnar.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any
such state or jurisdiction.
About Scopus BioPharma
Scopus BioPharma Inc. is a biopharmaceutical company developing
transformational therapeutics capitalizing on groundbreaking
scientific and medical discoveries from leading research and
academic institutions. The company's lead drug candidate is a
novel, targeted immuno-oncology gene therapy for the treatment of
multiple cancers. The company is also developing additional
new chemical entities to treat other serious diseases with
significant unmet medical needs, including systemic sclerosis.
Forward-Looking Statements
This press release may include forward-looking statements that
involve risks and uncertainties. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements are subject to risks (including those set forth in the
company's offering circular filed with the U.S. Securities and
Exchange Commission) and uncertainties which could cause actual
results to differ from the forward-looking statements. The company
expressly disclaims any obligations or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the company's
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Investors should realize that if our underlying assumptions for the
projections contained herein prove inaccurate or that known or
unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections.
Contact
Rodd Leeds/David Waldman
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: SCPS@crescendo-ir.com
View original
content:http://www.prnewswire.com/news-releases/scopus-biopharma-announces-closing-of-initial-public-offering-301196139.html
SOURCE Scopus BioPharma Inc.